1. Home
  2. IMNM vs KYN Comparison

IMNM vs KYN Comparison

Compare IMNM & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.07

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

HOLD

Current Price

$13.70

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
KYN
Founded
2006
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IMNM
KYN
Price
$18.07
$13.70
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$32.80
N/A
AVG Volume (30 Days)
1.2M
390.1K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
8.99%
EPS Growth
51.40
N/A
EPS
N/A
0.71
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,127.34
N/A
P/E Ratio
N/A
$19.82
Revenue Growth
N/A
N/A
52 Week Low
$7.96
$11.31
52 Week High
$27.65
$14.70

Technical Indicators

Market Signals
Indicator
IMNM
KYN
Relative Strength Index (RSI) 33.00 42.78
Support Level $16.81 $13.62
Resistance Level $19.16 $14.35
Average True Range (ATR) 0.92 0.25
MACD -0.21 -0.03
Stochastic Oscillator 1.24 17.85

Price Performance

Historical Comparison
IMNM
KYN

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: